I joined the faculty at the CU School of Pharmacy in 1998, and my early work focused on the stability of lipid-DNA complexes during freezing and drying. In attempting to assess “recovery” of these new pharmaceutical entities, I became interested in the mechanism by which they facilitated delivery to target cells. In over a decade of work, we eventually realized that these particles were being avidly taken up by circulating immune cells that elicited a potent cytokine response upon intravenous injection. In addition to our work attempting to exploit exosomes for drug delivery, our current projects investigate strategies that harness the nanoparticle-induced immune response to limit off-target accumulation of nanomedicines and promote tumor regression. In addition to these projects, my lab is constantly involved in multiple formulation studies that utilize small molecules to treat a variety of diseases.